An exploratory study of FDA new drug review times, Prescription Drug User Fee Acts, and R&D spending
Year of publication: |
2009
|
---|---|
Authors: | Vernon, John A. ; Golec, Joseph ; Lutter, Randall W. ; Nardinelli, Clark |
Published in: |
The quarterly review of economics and finance : journal of the Midwest Economics Association ; journal of the Midwest Finance Association. - Amsterdam [u.a.] : Elsevier, ISSN 1062-9769, ZDB-ID 1114217-0. - Vol. 49.2009, 4, p. 1260-1274
|
Subject: | Arzneimittel | Pharmaceuticals | Aufsichtsbehörde | Regulatory agency | Industrieforschung | Industrial research | Forschungskosten | Research expenditure | USA | United States | 1990-1999 |
-
Patents and R&D Expenditure Effects on Equity Returns in Pharmaceutical Industry
Feyzrakhmanova, Martina, (2015)
-
(2003)
-
Pharmaceutical policy change and the safety of new drugs
Olson, Mary K., (2002)
- More ...
-
Black Box Warnings and Drug Safety : Examining the Determinants and Timing of Fda Warning Labels
Begosh, Allan, (2013)
-
Pharmaceutical R&D spending and threats of price regulation
Golec, Joseph, (2010)
-
Drug development costs when financial risk is measured using the Fama-French three-factor model
Vernon, John A., (2010)
- More ...